Jennifer Peppe is a clinical researcher with more than 25 years of experience. As the Senior Vice President, Clinical Operations at Imago, she oversees all operational aspects of the global clinical development programs. Ms. Peppe is a founding employee of Imago.
Prior to joining Imago, Ms. Peppe joined FerroKin BioSciences in 2010 as Vice President, Clinical Operations at the time of Shire Pharmaceuticals acquisition of FerroKin in 2012.
Prior to joining FerroKin BioSciences, she was an Associate Director at Genzyme Corporation, where she worked for 12 years. While in clinical development at Genzyme, she managed Phase 1 through Phase 3 trials in various indications including: hypercholesterolemia, psoriasis, clostridium difficile-associated diarrhea (CDAD) and relapsing-remitting multiple sclerosis (MS). Within the CDAD program, she was the Global Study Lead responsible for oversight of two identical Phase 3 trials which were initiated in 16 countries at ~300 sites, enrolling greater than 1100 patients. Within the MS program, her responsibilities included cross functional team leadership for a global Phase 2 trial, as well as oversight of an expansive Risk Management Program. She began her clinical research career as consortium lead study coordinator at the Dana-Farber Cancer Institute where she spent five years working on a Phase 4 pediatric acute lymphoblastic leukemia trial.
Ms. Peppe received a Bachelor of Arts degree in psychology from Smith College.